Article
The U.S. Food and Drug Administration (FDA) is warning the public about "adverse events" associated with some "permanent" makeup treatments.
Johnson & Johnson Submits 2 sBLAs for Guselkumab for Pediatric Psoriasis and Juvenile PsA
The Cutaneous Connection: Combatting Treatment Skepticism in Advanced Pediatric Atopic Dermatitis
Shanna Miranti, MPAS, PA-C, Shares Expert Acne and Pediatric Dermatology Insights
The Cutaneous Connection: Episode 28- The Path to Understanding Pediatric Melanoma
Elimination Diets Have Little Impact on Pediatric Atopic Dermatitis, New Study Finds
Combination of Abrocitinib and Dupilumab Effectively Treats Pediatric Atopic Dermatitis